Lexeo Therapeutics, Inc. (LXEO) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US52886X1072
Lexeo Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -109.26 m USD |
| EBIT | -106.00 m USD |
| Net income | -99.96 m USD |
| Diluted EPS – continuing operations | -1.86 USD |
Full history since 2020, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has a license agreement with Cornell University to conduct the Phase 1/2 clinical trial of LX1001, as well as support the development of the LX1004 program; a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.
More stocks
- British American Tobacco Malaysia Bhd (4162.KL)
- Asia Neo Tech Industrial Co.,Ltd. (4542.TWO)
- BenQ Materials Corp (8215.TW)
- SISB Public Company Limited (SISB.BK)
- Relais Group Oyj (RELAIS.HE)
- NATIONAL BANKSHARES INC (NKSH)
- Super-Dragon Engineering Plastics Co. Ltd (301131.SZ)
- Bus Online Co Ltd (002188.SZ)
- Taiwan Sanyo Electric Co Ltd (1614.TW)
- Hyundai Hyms Co., Ltd. (460930.KQ)
- PT Indokripto Koin Semesta Tbk (COIN.JK)
- Quantum-Si Inc (QSI)
Not investment advice. All data without warranty, price as of 10.11.2026. Details in the risk notice.